Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Antoinette Moran; Brian Bundy; Dorothy J Becker; Linda A DiMeglio; Stephen E Gitelman; Robin Goland; Carla J Greenbaum; Kevan C Herold; Jennifer B Marks; Philip Raskin; Srinath Sanda; Desmond Schatz; Diane K Wherrett; Darrell M Wilson; Jeffrey P Krischer; Jay S Skyler; Linda Pickersgill; Eelco de Koning; Anette-G Ziegler; Bernhard Böehm; Klaus Badenhoop; Nanette Schloot; Jens Friis Bak; Paolo Pozzilli; Didac Mauricio; Marc Y Donath; Luis Castaño; Ana Wägner; Hans Henrik Lervang; Hans Perrild; Thomas Mandrup-Poulsen; Type 1 Diabetes TrialNet Canakinumab Study Group

doi:10.1016/S0140-6736(13)60023-9

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Antoinette Moran, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Carla J Greenbaum, Kevan C Herold, Jennifer B Marks, Philip Raskin, Srinath Sanda, Desmond Schatz, Diane K Wherrett, Darrell M Wilson, Jeffrey P Krischer, Jay S Skyler, Linda Pickersgill, Eelco de Koning, Anette-G Ziegler, Bernhard BöehmKlaus Badenhoop, Nanette Schloot, Jens Friis Bak, Paolo Pozzilli, Didac Mauricio, Marc Y Donath, Luis Castaño, Ana Wägner, Hans Henrik Lervang, Hans Perrild, Thomas Mandrup-Poulsen, Type 1 Diabetes TrialNet Canakinumab Study Group

IKM

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

315 Citationer (Scopus)

Abstract

Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediator interleukin-1 have been done. We aimed to assess whether canakinumab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved β-cell function in recent-onset type 1 diabetes.

Originalsprog	Engelsk
Tidsskrift	Lancet
Vol/bind	381
Udgave nummer	9881
Sider (fra-til)	1905-15
Antal sider	11
ISSN	0140-6736
DOI	https://doi.org/10.1016/S0140-6736(13)60023-9
Status	Udgivet - 1 jun. 2013

Adgang til dokumentet

10.1016/S0140-6736(13)60023-9

Citationsformater

Moran, A., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J., Herold, K. C., Marks, J. B., Raskin, P., Sanda, S., Schatz, D., Wherrett, D. K., Wilson, D. M., Krischer, J. P., Skyler, J. S., Pickersgill, L., de Koning, E., Ziegler, A.-G., ... Type 1 Diabetes TrialNet Canakinumab Study Group (2013). Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet, 381(9881), 1905-15. https://doi.org/10.1016/S0140-6736(13)60023-9

Moran, A, Bundy, B, Becker, DJ, DiMeglio, LA, Gitelman, SE, Goland, R, Greenbaum, CJ, Herold, KC, Marks, JB, Raskin, P, Sanda, S, Schatz, D, Wherrett, DK, Wilson, DM, Krischer, JP, Skyler, JS, Pickersgill, L, de Koning, E, Ziegler, A-G, Böehm, B, Badenhoop, K, Schloot, N, Bak, JF, Pozzilli, P, Mauricio, D, Donath, MY, Castaño, L, Wägner, A, Lervang, HH, Perrild, H , Mandrup-Poulsen, T & Type 1 Diabetes TrialNet Canakinumab Study Group 2013, 'Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials', Lancet, bind 381, nr. 9881, s. 1905-15. https://doi.org/10.1016/S0140-6736(13)60023-9

@article{48e159d475264aaab6b9be91062dcd22,

title = "Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials",

abstract = "Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediator interleukin-1 have been done. We aimed to assess whether canakinumab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved β-cell function in recent-onset type 1 diabetes.",

keywords = "Adolescent, Adult, Analysis of Variance, Antibodies, Monoclonal, C-Peptide, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Immunologic Factors, Insulin-Secreting Cells, Interleukin 1 Receptor Antagonist Protein, Interleukin-1, Male, Treatment Outcome, Young Adult",

author = "Antoinette Moran and Brian Bundy and Becker, {Dorothy J} and DiMeglio, {Linda A} and Gitelman, {Stephen E} and Robin Goland and Greenbaum, {Carla J} and Herold, {Kevan C} and Marks, {Jennifer B} and Philip Raskin and Srinath Sanda and Desmond Schatz and Wherrett, {Diane K} and Wilson, {Darrell M} and Krischer, {Jeffrey P} and Skyler, {Jay S} and Linda Pickersgill and {de Koning}, Eelco and Anette-G Ziegler and Bernhard B{\"o}ehm and Klaus Badenhoop and Nanette Schloot and Bak, {Jens Friis} and Paolo Pozzilli and Didac Mauricio and Donath, {Marc Y} and Luis Casta{\~n}o and Ana W{\"a}gner and Lervang, {Hans Henrik} and Hans Perrild and Thomas Mandrup-Poulsen and {Type 1 Diabetes TrialNet Canakinumab Study Group}",

year = "2013",

month = jun,

day = "1",

doi = "10.1016/S0140-6736(13)60023-9",

language = "English",

volume = "381",

pages = "1905--15",

journal = "Lancet",

issn = "0140-6736",

publisher = "TheLancet Publishing Group",

number = "9881",

}

TY - JOUR

T1 - Interleukin-1 antagonism in type 1 diabetes of recent onset

T2 - two multicentre, randomised, double-blind, placebo-controlled trials

AU - Moran, Antoinette

AU - Bundy, Brian

AU - Becker, Dorothy J

AU - DiMeglio, Linda A

AU - Gitelman, Stephen E

AU - Goland, Robin

AU - Greenbaum, Carla J

AU - Herold, Kevan C

AU - Marks, Jennifer B

AU - Raskin, Philip

AU - Sanda, Srinath

AU - Schatz, Desmond

AU - Wherrett, Diane K

AU - Wilson, Darrell M

AU - Krischer, Jeffrey P

AU - Skyler, Jay S

AU - Pickersgill, Linda

AU - de Koning, Eelco

AU - Ziegler, Anette-G

AU - Böehm, Bernhard

AU - Badenhoop, Klaus

AU - Schloot, Nanette

AU - Bak, Jens Friis

AU - Pozzilli, Paolo

AU - Mauricio, Didac

AU - Donath, Marc Y

AU - Castaño, Luis

AU - Wägner, Ana

AU - Lervang, Hans Henrik

AU - Perrild, Hans

AU - Mandrup-Poulsen, Thomas

AU - Type 1 Diabetes TrialNet Canakinumab Study Group

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediator interleukin-1 have been done. We aimed to assess whether canakinumab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved β-cell function in recent-onset type 1 diabetes.

AB - Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediator interleukin-1 have been done. We aimed to assess whether canakinumab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved β-cell function in recent-onset type 1 diabetes.

KW - Adolescent

KW - Adult

KW - Analysis of Variance

KW - Antibodies, Monoclonal

KW - C-Peptide

KW - Child

KW - Diabetes Mellitus, Type 1

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Hypoglycemic Agents

KW - Immunologic Factors

KW - Insulin-Secreting Cells

KW - Interleukin 1 Receptor Antagonist Protein

KW - Interleukin-1

KW - Male

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1016/S0140-6736(13)60023-9

DO - 10.1016/S0140-6736(13)60023-9

M3 - Journal article

C2 - 23562090

SN - 0140-6736

VL - 381

SP - 1905

EP - 1915

JO - Lancet

JF - Lancet

IS - 9881

ER -